Revisiones en Cáncer 00050 / http://dx.doi.org/10.20960/revcancer.00050

Resumen| PDF

Revisión

Quimioterapia en el cáncer de próstata hormono-naïve

David Humberto Marmolejo, Rafael Morales-Barrera, Macarena González, Cristina Suárez, Pablo Cresta, Joaquín Mateo, Joan Carles

Prepublicado: 2024-02-14

Publicado: 2024-03-06

VOLUMEN 37, NÚM. 6, noviembre-diciembre (2023), PAG. 293-301

Logo Descargas Número de descargas: 25535 Logo Visitas Número de visitas: 1110 Citas Citas: 0

Compártelo:

El paradigma de tratamiento del cáncer de próstata metastásico ha evolucionado rápidamente en los últimos años. El pilar del tratamiento en la enfermedad metastásica continúa siendo la terapia de deprivación de andrógenos, pero la intensificación del tratamiento con la adición de quimioterapia y de los nuevos inhibidores de la vía del receptor de andrógenos (dobletes y tripletes) han proporcionado mejoras significativas en la supervivencia en el escenario hormono-sensible, retrasando la progresión a la resistencia a la castración y mejorando la calidad de vida de los pacientes. Sin embargo, surgen controversias sobre el beneficio de la terapia de intensificación y la selección óptima del tratamiento según el escenario clínico de cada paciente.

Palabras Clave: Cáncer de próstata. Quimioterapia. Hormonosensible. Metastásico. Docetaxel.

Descargar PDF

Bibliografía
Artículos Relacionados

Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249.
DOI: 10.3322/caac.21660

Las cifras del cáncer en España, último acceso 18/11/2023, disponible en https://seom.org/prensa/el-cancer-en-cifras

Wu JN, Fish KM, Evans CP, et al. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014;120:818–23.
DOI: 10.1002/cncr.28485

Adams J. The case of scirrhous of the prostate gland with corresponding affliction of the lymphatic glands in the lumbar region and in the pelvis. Lancet. 1853;1:393.

Huggins C, Hodges CV. Studies on prostatic cancer: The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J Clin. 1972;22:232–40.
DOI: 10.3322/canjclin.22.4.232

Tangen CM, Hussain MH, Higano CS, et al. Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 2012; 188: 1164–1169.
DOI: 10.1016/j.juro.2012.06.046

Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 2015; 373: 737–746.

De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 2011; 364: 1995–2005.

De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open label trial. Lancet 2010; 376: 1147–1154.
DOI: 10.1016/S0140-6736(10)61389-X

Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 2010; 363: 411–422.

Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 2013; 369: 213–223.

Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 2012; 367: 1187–1197.

Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004; 351: 1502–1512.

de Bono J, Mateo J, Fizazi K, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2020 May 28;382(22):2091-2102.
DOI: 10.1056/NEJMoa1911440

Fizazi K, Piulats JM, Reaume MN, et al; TRITON3 Investigators. Rucaparib or Physician's Choice in Metastatic Prostate Cancer. N Engl J Med. 2023 Feb 23;388(8):719-732.
DOI: 10.1056/NEJMoa2214676

Sartor O, de Bono J, Chi KN, et al; VISION Investigators. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021 Sep 16;385(12):1091-1103.
DOI: 10.1056/NEJMoa2107322

Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone‑resistant prostate cancer. Cancer 1993; 71: 1098–109.
DOI: 10.1002/1097-0142(19930201)71:3+<1098::AID-CNCR2820711432>3.0.CO;2-G

Noguchi M, Noda S, Yoshida M, et al. Chemohormonal therapy as primary treatment for metastatic prostate cancer: a randomized study of estramustine phosphate plus luteinizing hormone-releasing hormone agonist versus flutamide plus luteinizing hormone-releasing hormone agonist. Int. J. Urol. 2004;11: 103–9.20
DOI: 10.1111/j.1442-2042.2004.t01-1-00748.x

Pummer K, Lehnert M, Stettner H, Hubmer G. Randomized comparison of total androgen blockade alone versus combined with weekly epirubicin in advanced prostate cancer. Eur. Urol. 1997;32(Suppl. 3): 81–5.21

Pummer K. Epirubicin plus flutamide and orchidectomy in previously untreated advanced prostatic cancer. Semin Oncol. 1991 Oct;18(5 Suppl 6):26-8.

Murphy GP, Beckley S, Brady MF, et al. Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 1983;51: 1264–72.22
DOI: 10.1002/1097-0142(19830401)51:7<1264::AID-CNCR2820510716>3.0.CO;2-U

Millikan RE, Wen S, Pagliaro LC, et al. Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer. J. Clin. Oncol. 2008;26: 5936–42.

Kuriyama M, Takahashi Y, Sahashi M, et al. Prospective and randomized comparison of combined androgen blockade versus combination with oral UFT as an initial treatment for prostate cancer. Jpn J Clin Oncol. 2001 Jan;31(1):18-24.
DOI: 10.1093/jjco/hye008

Wang J, Halford S, Rigg A, et al. Adjuvant mitoxantrone chemotherapy in advanced prostate cancer. BJU Int. 2000 Oct;86(6):675-80.
DOI: 10.1046/j.1464-410x.2000.00894.x

Boel K, Van Poppel H, Goethuys H, et al. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial. Anticancer Res. 1999 May-Jun;19(3B):2157-61.

Osborne CK, Blumenstein B, Crawford ED, et al. Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group study. J Clin Oncol. 1990 Oct;8(10):1675-82.
DOI: 10.1200/JCO.1990.8.10.1675

Murphy GP, Huben RP, Priore R. Results of another trial of chemotherapy with and without hormones in patients with newly diagnosed metastatic prostate cancer. Urology. 1986 Jul;28(1):36-40.
DOI: 10.1016/0090-4295(86)90178-0

De Reijke TM, Keuppens FI, Whelan P, et al. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial. J Urol. 1999 Nov;162(5):1658-64; discussion 1664-5.
DOI: 10.1016/S0022-5347(05)68191-8

Janknegt RA, Boon TA, van de Beek C, Grob P. Combined hormono/chemotherapy as primary treatment for metastatic prostate cancer: a randomized, multicenter study of orchiectomy alone versus orchiectomy plus estramustine phosphate. The Dutch Estracyt Study Group. Urology 1997;49(3):411‐20.
DOI: 10.1016/S0090-4295(96)00496-7

Parimi S, Chi KN. Chemotherapy for metastatic castration-sensitive prostate cancer. Int J Urol. 2016 Sep;23(9):726-33.
DOI: 10.1111/iju.13148

Eigl BJ, Eggener SE, Baybik J, et al. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Clin Cancer Res. 2005 Jul 1;11(13):4905-11.
DOI: 10.1158/1078-0432.CCR-04-2140

Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, et al. Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res 2006; 12: 169–174.
DOI: 10.1158/1078-0432.CCR-05-1388

Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat.Rev. Cancer 2004;4: 253–65.

Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004;351: 1513–20

Darshan MS, Loftus MS, Thadani-Mulero M, et al.Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.Cancer Res.2011;71: 6019–29
DOI: 10.1158/0008-5472.CAN-11-1417

Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomized, open-label, phase 3 trial. Lancet Oncol 2013; 14: 149–158.
DOI: 10.1016/S1470-2045(12)70560-0

James ND, Sydes MR, Clarke NW, STAMPEDE investigators, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomized controlled trial. Lancet. 2016 Mar 19;387(10024):1163-77.

Miller RE, Sweeney CJ. Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2016 Jun;19(2):139-44.
DOI: 10.1038/pcan.2016.10

Gravis GB, Joly F, Oudard S, et al. Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (PCa): long-term analysis of the GETUG-AFU 15 phase III trial. J Clin Oncol 2015; 33: abstract 140
DOI: 10.1200/jco.2015.33.7_suppl.140

Kyriakopoulos CE, Chen YH, Carducci MA, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018 Apr 10;36(11):1080-1087.
DOI: 10.1200/JCO.2017.75.3657

Clarke NW, Ali A, Ingleby FC, et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol. 2019 Dec 1;30(12):1992-2003.
DOI: 10.1093/annonc/mdz248.001

Glass TR, Tangen CM, Crawford ED, et al. Metastatic carcinoma of the prostate: identifying prognostic groups using recursive partitioning. J Urol 2003; 169: 164–169.
DOI: 10.1016/S0022-5347(05)64059-1

Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N. Engl. J. Med. 1998; 339: 1036–1042.

Hussain M, Tangen CM, Berry DL, et al. Intermittent versus continuous androgen deprivation in prostate cancer. N. Engl. J. Med. 2013; 368: 1314–1325.

Tait C, Moore D, Hodgson C, et al. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival. BJU Int 2014; 114: E70–E73.
DOI: 10.1111/bju.12717

Vale CRL, Tierney JF, Albiges L, et al. What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses. Eur J Cancer 2015; 51: 20LBA.
DOI: 10.1016/S0959-8049(16)31941-4

Smith MR, Hussain M, Saad F, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. N Engl J Med. 2022;386(12):1132.
DOI: 10.1056/NEJMoa2119115

Hussain M, Tombal B, Saad F, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. J Clin Oncol. 2023 Jul 10;41(20):3595-3607.
DOI: 10.1200/JCO.23.00041

Fizazi K, Foulon S, Carles J, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomized, phase 3 study with a 2 × 2 factorial design. Lancet. 2022;399(10336):1695.
DOI: 10.1016/S0140-6736(22)00367-1

Davis ID, Martin AJ, Stockler MR, et al. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121.
DOI: 10.1056/NEJMoa1903835

Sweeney CJ, Martin AJ, Stockler MR, et al. ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomized, phase 3 trial. Lancet Oncol. 2023 Apr;24(4):323-334.

Roy S, Sayyid R, Saad F, et al. Addition of Docetaxel to Androgen Receptor Axis–targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. Eur. Urol. Oncol. 2022;5:494–502.

Naqvi SAA, Bin Riaz Z, Riaz A, et al. Triplet therapy in metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. J. Clin. Oncol. 2022;40:136.

Sathianathen NJ, Pan HYC, Lawrentschuk N, et al. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: An updated systematic review and network meta-analysis. Urol Oncol. 2023 May;41(5):233-239.
DOI: 10.1016/j.urolonc.2022.10.016

Riaz IB, Naqvi SAA, He H, et al. First-line Systemic Treatment Options for Metastatic Castration-Sensitive Prostate Cancer: A Living Systematic Review and Network Meta-analysis. JAMA Oncol. 2023:e227762.
DOI: 10.1001/jamaoncol.2022.7762

Hoeh B, Garcia CC, Wenzel M, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer: Updated Network Meta-analysis Stratified by Disease Volume. Eur Urol Focus. 2023 Apr 11:S2405-4569(23)00094-9.

Wenzel M, Würnschimmel C, Nocera L, et al. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. Eur Urol Focus. 2022 Mar;8(2):399-408.
DOI: 10.1016/j.euf.2021.04.003

George DJ, Agarwal N, Rider JR, et al. Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings. J. Clin. Oncol. 2021;39:5074.

Swami U, Hong A, El-Chaar NN, et al. Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. J. Clin. Oncol. 2021;39:5072.

Mittal A, Sridhar SS, Ong M, Jiang DM. Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)-A Potential New Standard of Care. Curr Oncol. 2023 Apr 20;30
DOI: 10.3390/curroncol30040332

Revisión: Quimiorradiación del cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Quimioterapia en cáncer de esófago

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento sistémico del cáncer en el paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Manejo del linfoma agresivo del paciente anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Opciones terapéuticas en gliomas de alto grado del anciano

Publicado: 2022-07-26 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer ginecológico en la anciana

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Cáncer de próstata en el anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de colon en el anciano

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento perioperatorio del cáncer gástrico

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF

Revisión: Tratamiento médico del cáncer de estómago recurrente y metastásico en primera línea

Publicado: 2022-07-28 / http://dx.doi.org/

Resumen | PDF